A cash-rich gene-therapy pioneer with blockbuster-quality Huntington’s data—but a hostile FDA has turned the path to approval into a sham-surgery gauntlet.
Overview
uniQure N.V. (NASDAQ: QURE) is an early pioneer in AAV gene therapy developing potentially curative, one-time treatments for severe genetic and neurodegenerative diseases. Its platform has already produced a landmark commercial outcome: HEMGENIX, the first gene therapy approved by both FDA and EMA for adults with severe/moderately severe Hemophilia B. Importantly, uniQure chose not to commercialize HEMGENIX itself, instead licensing global commercialization to CSL Behring—transforming uniQure from a vertically integrated commercial/manufacturing company into a leaner, clinical-stage R&D organization. Today, uniQure’s revenue model is primarily partner-derived: royalties on global net sales of HEMGENIX plus milestone payments. A major 2024 pivot further reshaped the company: it sold its Lexington, MA manufacturing facility to Genezen, permanently eliminating contract manufacturing revenue but reducing fixed costs and cash burn. The core forward value rests on its wholly owned pipeline led by AMT-130 for Huntington’s disease, an invasive intrastriatal AAV5 microRNA approach intended as a one-time disease-modifying intervention. Despite highly compelling 36-month Phase I/II data suggesting a 75% slowing of disease progression and multiple FDA designations (Breakthrough, RMAT, Orphan, Fast Track), uniQure encountered an unprecedented regulatory shock in early 2026: the FDA rejected an accelerated BLA strategy based on external natural-history controls and required a randomized, sham-surgery-controlled Phase III study. This pushes timelines out several years and raises ethical, logistical, and cost barriers. Offsetting this, uniQure is unusually well-capitalized: it ended 2025 with $622.5M in cash/investments, guiding runway into 2H 2029. The investment profile is polarized—regulatory volatility and trial feasibility risk versus a cash-backed valuation floor and potentially asymmetric upside if the regulatory path reopens.